Our Annual Review 2019

Download our 2019 Annual Review here.

Latest

Dundee Edinburgh Parkinson's Research Initiative Symposium

For scientists - This is an exciting day of talks and discussion on Parkinson's disease brought to you by researchers from Dundee and Edinburgh.
Dundee Edinburgh Parkinson's Research Initiative

This event, supported by CPT, will be the 3rd public event about Parkinson's clinical research in Lothian and Tayside with a stimulating panel discussion.
Take on your own cycle challenge for CPT

Discover many of the fantastic cycling events taking place in the UK throughout the year here. If you're already taking on your own challenge raising funds for The Cure Parkinson's Trust, we would love to hear from you.
Herantis Pharma: Phase 1/2 CDNF Topline Results

Herantis Pharma Plc have announced that their ongoing Phase 1-2 clinical trial testing the neuroprotective agent ‘cerebral dopamine neurotrophic factor’ (or CDNF) in people with Parkinson’s has met its primary endpoint

Herantis Pharma: Phase 1/2 CDNF Topline Results

Herantis Pharma Plc have announced that their ongoing Phase 1-2 clinical trial testing the neuroprotective agent ‘cerebral dopamine neurotrophic factor’ (or CDNF) in people with Parkinson’s has met its primary endpoint
Earlier Diagnosis and Treatment of Dementia in Parkinson's

Recently published research from UCL suggests monitoring of levels of iron in people with Parkinson's may help with early diagnosis and earlier treatment of dementia
GDNF and Cell Transplantation: Dual therapies for Parkinson's

Scientists in Australia have recently published pre-clinical research exploring multiple treatment approaches for Parkinson's, in particular using GDNF alongside cell replacement therapy.
The Minnesota UDCA Clinical Study

Recently, researchers in Minnesota (USA) published the results of a small pilot clinical trial investigating the safety of Ursodeoxycholic acid (or UDCA) in Parkinson's.
UDCA and Laboratory Cell-Based Parkinson's

Researchers at Sheffield and Oxford Universities have recently published research exploring 'subtypes' of Parkinson's in cell-culture studies, which has highlighted a drug that The Cure Parkinson's Trust is clinically testing.
Similarities between Alzheimer's and Parkinson's

Two groups recently published independent journal articles suggesting that a genetic variation associated with Alzheimer's might also have an important influence in Parkinson's.
AEGIS Office2Office Ride 2020

This September, AEGIS London will be taking on the Castel Office2Office Ride, cycling from London to Amsterdam raising funds and awareness for The Cure Parkinson's Trust.
The International Linked Clinical Trials Programme for Parkinson's

The Cure Parkinson’s Trust and Van Andel Institute announce their agreement to pledge USD $4.5 million to research, strengthening an already thriving global programme to further develop new, potentially disease-modifying Parkinson’s therapies.
A Sub-Study Investigating Azathioprine in Parkinson's

In Parkinson’s there appears to be an over-abundance of inflammatory cells in the brain. This study will examine how azathioprine impacts this inflammation to determine whether this drug could be a future treatment for Parkinson's.
New Developments In Diabetes Drugs for Parkinson's

At the forefront of treatments for diabetes is a class of drug called glucagon-like peptide 1 receptor (GLP-1R) agonists. There is now considerable evidence that suggest GLP-1R diabetes drugs could potentially be used in the treatment of Parkinson's.

Breakthrough in stem cell treatment for Parkinson's

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.
Tom Isaacs

We are devastated to announce that Tom Isaacs, President and Co-founder of The Cure Parkinson’s Trust (CPT) died on Wednesday morning (31st May). Tom’s passing was unexpected and swift.
New Evidence Suggests Parkinson's Might Not Start in The Brain

A new study adds to a raft of new evidence which suggests Parkinson's starts in the gut...
Science news

Read the latest Parkinson's science and research news here.
Trials - Repurposed Drugs

Our International Linked Clinical Trials initiative (iLCT) identifies potential new treatments to slow, stop or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.
Apply for Funding
The NAC Trial - the facts
Our story
Diabetes Drug Potential Disease-Modifying Therapy

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.
Alpha-synuclein and Parkinson's

Science news

Read the latest Parkinson's science and research news here. Read more

The Cure Collective

The Cure Collective is an opportunity to join like-minded individuals who are committed to help drive forward the quest to find a cure for Parkinson’s... Read more

Our Annual Review 2019

Our Annual Review 2019 - your online publication here... Read more